RT Journal Article
SR Electronic
T1 In Vivo CRISPR Gene Editing in Patients with Herpes Stromal Keratitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.21.23285822
DO 10.1101/2023.02.21.23285822
A1 Wei, Anji
A1 Yin, Di
A1 Zhai, Zimeng
A1 Ling, Sikai
A1 Le, Huangying
A1 Tian, Lijia
A1 Xu, Jianjiang
A1 Paludan, Soren R
A1 Cai, Yujia
A1 Hong, Jiaxu
YR 2023
UL http://medrxiv.org/content/early/2023/02/24/2023.02.21.23285822.abstract
AB In vivo CRISPR gene therapy holds large clinical potential, but the safety and efficacy remain largely unknown. Here, we injected a single dose of HSV-1-targeting CRISPR formulation in the cornea of three patients with severe refractory herpes stromal keratitis (HSK) during corneal transplantation. Our study is an investigated initiated, open-label, single-arm, non-randomized interventional trial at a single center (NCT04560790). We found neither detectable CRISPR-induced off-target cleavages by GUIDE-seq nor systemic adverse events for 18 months on average in all three patients. The HSV-1 remained undetectable during the study. Our preliminary clinical results suggest that in vivo gene editing targeting the HSV-1 genome holds acceptable safety as a potential therapy for HSK.One-Sentence Summary Our study is the first in vivo CRISPR therapy for treating infectious disease and the first virus-like particle (VLP)-delivered gene therapy, reporting clinical follow-up to 21 months in HSK patients without seeing virus relapse, HSK recurrence, and CRISPR-associated side effects.Competing Interest StatementY.C. is a co-founder and advisor of BDgene Therapeutics. S.L. is currently an employee of BDgene Therapeutics. The other authors declare no competing interests.Clinical TrialNCT04560790Funding StatementNational Natural Science Foundation of China 81970766 (J.H.) National Natural Science Foundation of China 82171102 (J.H.) National Natural Science Foundation of China 31971364 (Y.C.) Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (J.H.) Shanghai Innovation Development Program 2020-RGZN-02033 (J.H.) Shanghai Key Clinical Research Program SHDC2020CR3052B (J.H.) Key forward-looking layout fund from Shanghai Jiao Tong University AF4150049 (Y.C.) National Key R&D Program of China 2022YFC3400200 (Y.C.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical practice was approved by the ethics committee of the Eye & ENT Hospital of Fudan University, China, the National Health Commission, China (IRB- 220113) and registered with ClinicalTrials.gov (NCT04560790). Written informed consent was provided by the patients under video recording. The healthy donors involved in this study all signed the informed consent for biological sample donation and data sharing before the operation, with an agreement that the samples should be used for biomedical research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all data supporting the findings of this study are available within the paper and its extended data and supplementary information files. The deep-sequencing data for 293T and patient samples are available at NCBI BioProject. The BioProject IDs are PRJNA823566 and PRJNA823861, respectively. The GUIDE-seq preliminary data is shown on NCBI BioProject with an ID of PRJNA857843. No custom code or mathematical algorithm is used for this study.